CTKB logo

Cytek Biosciences (CTKB)

Profile

Full Name

Cytek Biosciences, Inc.

Ticker Symbol

CTKB

Exchange

NASDAQ

Country

United States

IPO

July 23, 2021

Indexes

Not included

Employees

648

Key Details

Price

$3.63(-1.23%)

Market cap

$464.35M(Small cap)

Last Dividend

-

TTM Dividend yield

-

Annual revenue

$200.45M(+3.85% YoY)

Annual EPS

-$0.05(+44.44% YoY)

PE ratio

-

Next earnings date

May 8, 2025

Next ex-dividend date

N/A

Next split date

N/A

Price

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price Performance

Price Range

Capitalization

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Market cap

Shares Outstanding

Technical Indicators

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Income Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

EPS

Profit

Expenses

EBIT & EBITDA

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Liabilities

Debt

Equity & Capital

Cash Flow Statement

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

CAPEX

Free Cash Flow

Profitability Ratios

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Margins

ROA & ROE

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Analyst ratings

Recent major analysts updates

Mar 19, 25 Stephens & Co.
Overweight
Mar 4, 25 Piper Sandler
Overweight
Nov 11, 24 Piper Sandler
Overweight
Aug 13, 24 Piper Sandler
Overweight
May 13, 24 Piper Sandler
Overweight
Mar 6, 24 Piper Sandler
Overweight
Feb 29, 24 Goldman Sachs
Buy
Dec 14, 23 Stephens & Co.
Overweight
Nov 9, 23 Morgan Stanley
Equal-Weight
Oct 24, 23 Morgan Stanley
Equal-Weight

Institutional Ownership

  • What is the ticker symbol for Cytek Biosciences?
  • Does Cytek Biosciences pay dividends?
  • What sector is Cytek Biosciences in?
  • What industry is Cytek Biosciences in?
  • What country is Cytek Biosciences based in?
  • When did Cytek Biosciences go public?
  • Is Cytek Biosciences in the S&P 500?
  • Is Cytek Biosciences in the NASDAQ 100?
  • Is Cytek Biosciences in the Dow Jones?
  • When was Cytek Biosciences's last earnings report?
  • When does Cytek Biosciences report earnings?
  • Should I buy Cytek Biosciences stock now?

What is the ticker symbol for Cytek Biosciences?

The ticker symbol for Cytek Biosciences is NASDAQ:CTKB

Does Cytek Biosciences pay dividends?

No, Cytek Biosciences does not pay dividends

What sector is Cytek Biosciences in?

Cytek Biosciences is in the Healthcare sector

What industry is Cytek Biosciences in?

Cytek Biosciences is in the Medical Devices industry

What country is Cytek Biosciences based in?

Cytek Biosciences is headquartered in United States

When did Cytek Biosciences go public?

Cytek Biosciences's initial public offering (IPO) was on July 23, 2021

Is Cytek Biosciences in the S&P 500?

No, Cytek Biosciences is not included in the S&P 500 index

Is Cytek Biosciences in the NASDAQ 100?

No, Cytek Biosciences is not included in the NASDAQ 100 index

Is Cytek Biosciences in the Dow Jones?

No, Cytek Biosciences is not included in the Dow Jones index

When was Cytek Biosciences's last earnings report?

Cytek Biosciences's most recent earnings report was on Feb 27, 2025

When does Cytek Biosciences report earnings?

The next expected earnings date for Cytek Biosciences is May 8, 2025

Should I buy Cytek Biosciences stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions
On this page